BioCytics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

BioCytics is a North Carolina-based biotech company with a dual business model combining internal cell therapy development with external contract services. Its internal pipeline centers on autologous immune cell therapies, particularly Tumor-Infiltrating Lymphocytes (TILs), for solid tumors, having recently achieved a key regulatory milestone with an FDA INTERACT meeting. Externally, the company generates revenue and de-risks its platform by providing CDMO, CRO, and biobanking services to industry partners, leveraging its expertise in cell therapy process development and GMP manufacturing.

Oncology

Technology Platform

Autologous immune cell therapy platform (BioDICE) focused on Tumor-Infiltrating Lymphocytes (TILs) and point-of-care manufacturing.

Opportunities

The growing cell therapy market, especially for solid tumors, presents a major opportunity for its internal pipeline.

Simultaneously, the booming CDMO/CRO demand for cell therapy services provides a steady revenue stream and de-risks its business model.

Innovations in point-of-care manufacturing could be a key differentiator.

Risk Factors

Scientific and clinical risks inherent in developing novel TIL therapies for solid tumors.

Regulatory hurdles in gaining FDA approval for its platform and therapies.

Intense competition from larger, well-funded biopharma companies in the cell therapy space.

Competitive Landscape

BioCytics competes in the crowded and fast-evolving cell therapy for oncology space, facing large CDMOs (e.g., Lonza, Catalent) in services and numerous biotechs/pharma (e.g., Iovance, Instil Bio) in TIL therapeutics. Its differentiation lies in its integrated, clinic-adjacent model and focus on point-of-care manufacturing logistics.

More companies in Diagnostics & Precision Medicine →More companies in United States →